The Food and Drug Administration approved Johnson & Johnson's nasal spray ... first-ever stand-alone therapy for treatment-resistant depression, which is when trying at least two standard ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the standalone treatment of major depressive disorder (MDD), PTSD, and similar ...

Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...

The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...

Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...

For people with AD, Johnson & Johnson's research offers hope ... “Many patients with AD have higher rates of depression, anxiety, stress and suicide,” she says. Existing treatments for AD ...

Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...